ETON
$58.45
+$17.67 (43.31%)+43.31%
OpenLoading chart...
IndexN/A
Market Cap1.60B
Enterprise Value0.46B
Income$-0.00B
Sales$0.02B
EmployeesN/A
P/E-835.29
P/S5.69
P/B17.40
P/C44.65
EV/EBITDA107.83
EV/SalesN/A
EPS (ttm)-0.07
EarningsN/A
Gross Margin53.46%
Oper. Margin0.09%
Profit Margin-5.75%
Volume1.90M
Shs Outstand0.03B
Change43.31%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.01M | $31.64M | $21.25M | $21.83M | $39.00K | $959.00K | $0.00 | $0.00 |
| Cost of Revenue | $15.60M | $10.58M | $6.93M | $2.62M | $286.00K | $453.00K | $63.00K | $13.00K |
| Gross Profit | $23.41M | $21.06M | $14.32M | $19.21M | $-247.00K | $506.00K | $-63.00K | $-13.00K |
| Gross Margin | 60.01% | 66.56% | 67.38% | 87.99% | -633.33% | 52.76% | N/A | N/A |
| Operating Expenses | $26.01M | $22.25M | $22.58M | $20.70M | $26.86M | $19.11M | $10.26M | $7.14M |
| Operating Income | $-2.60M | $-1.19M | $-8.26M | $-1.50M | $-27.11M | $-18.60M | $-10.32M | $-7.15M |
| Operating Margin | -6.66% | -3.77% | -38.87% | -6.85% | -69515.38% | -1939.62% | N/A | N/A |
| Net Income | $-3.82M | $-936.00K | $-9.02M | $-1.96M | $-27.97M | $-18.32M | $-12.74M | $-7.16M |
| Net Margin | -9.80% | -2.96% | -42.45% | -8.95% | -71717.95% | -1910.32% | N/A | N/A |
| EPS (Basic) | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | $-1.02 | $-1.99 | $-0.41 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $76.12M | $31.74M | $25.03M | $27.46M | $26.32M | $17.07M | $28.33M | $13.44M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $51.70M | $16.26M | $11.95M | $9.84M | $10.66M | $6.52M | $2.02M | $1.31M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $24.43M | $15.48M | $13.08M | $17.63M | $15.66M | $10.55M | $26.30M | $12.13M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $24.43M | $15.48M | $13.08M | $17.63M | $15.66M | $10.55M | $26.30M | $12.13M |
| Total Liabilities & Stockholders Equity | $76.12M | $31.74M | $25.03M | $27.46M | $26.32M | $17.07M | $28.33M | $13.44M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-3.82M | $-936.00K | $-9.02M | $-1.96M | $-27.97M | $-18.32M | $-12.74M | $-7.16M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $969.00K | $6.82M | $4.82M | $-4.72M | $-22.35M | $-18.03M | $-8.14M | $-4.72M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001GlobeNewswire Inc. Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026GlobeNewswire Inc. Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral SolutionBenzinga Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral SolutionGlobeNewswire Inc. Eton Pharmaceuticals Reports First Quarter 2024 Financial ResultsGlobeNewswire Inc. Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceGlobeNewswire Inc. Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)GlobeNewswire Inc. Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024GlobeNewswire Inc.
Show 12 more stories
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaGlobeNewswire Inc. Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire Inc. Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024GlobeNewswire Inc. Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?Zacks Investment Research Moderna (MRNA) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid FormulationGlobeNewswire Inc. Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone CapsulesGlobeNewswire Inc. 5 Under-$15 Stocks Wall Street Analysts Recommend BuyingZacks Investment Research Eton Pharmaceuticals Reports Third Quarter 2023 Financial ResultsGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Discover more
You may be interested in